Genmab — Juni 2020

nohope

Livmoderhalskræft er vel en sygdom så vi vil se forsvinde over den kommende tid. Den kan vaccineres væk. At der er tåber der heller ser deres døtre dø af livmoderhalskræft end få et stik slipper vel op.

Bulder

Ja, det er det der er spørgsmålet. I Australien regner man med om få år at have udryddet lmhk, fordi tilslutningen til vacc-programmet er 100%. I Japan derimod er det tæt på 0%.

Bulder

I DK er stemningen vel ved at vende til fordel for vacc. I US er det bob bob. Så der vil gå en årrække med et marked for lmhk-terapier.

Bulder

Og til den tid har TV måske vist sig effektiv i en række andre solide tumorer.

E_L

it will still take some time for this to disappear, have another look at the Cervical Cancer Market Size, p35 June investor prestentation, shocking how many
still die in Europe https://ir.genmab.com/download-library#content

E_L

I posted this seekingalpha article a while ago, as it also looked at cervical cancer https://seekingalpha.com/article/4335715-agenus-time-of-coronavirus

Bulder

Yes I was quite surprised on European numbers. What countries are they that bring the numbers so high?

E_L

don't know, good question. I know in the netherlands it is only 200 -250, we have large cervical cancer screening programmes

E_L

HPV Vaccination here is around 70% i believe, by chance it was in the newspaper that this year it went up by 7%

E_L

this morning

nohope

When will it be available for commercial use ? In 5-10 years ? At that time we hopefully(!) will see a sharp decline in cervical cancer due to vaccine.

GeorgeBest

Tiso will be available next year in 2nd line and onwards

GeorgeBest

In US at least

nohope

Ok. Let´s hope that it will be of benefit to both the women - and us.

E_L

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) A/S on Tuesday, setting a price target of $40,

E_L

i actually thought they were already at $40

Monforte

@EL, you are right , see EL 11/6

kkjoel

They were. "He REITERATED a buy rating.." and apparently the same goes for the target (setting)...

bikube

ATH i U S 33,53 = 2229 Dkk

E_L

Seattle Genetics (SGEN) PT Raised to $210 at Oppenheimer on Positive Ph2 Tisotumab Vedotin (TV) Study